Q-omics provides the consensus-scored NFYCP2 profile across patient tissues and cancer cell-line models. NFYCP2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NFYCP2 is differentially expressed in 5, with the highest sampling consensus in KIRP. Additionally, NFYCP2 RNA expression shows 8,577 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRP, and LSCC as cancer lineages where NFYCP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NFYCP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NFYCP2 survival associations across molecular data types. NFYCP2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NFYCP2 RNA expression–survival associations across cancer types. High NFYCP2 expression shows unfavorable associations in ACC, LIHC, ESCA, LUAD and COAD, but favorable associations in SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify ACC as the clearest survival context for NFYCP2 RNA expression.
This table summarizes NFYCP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for NFYCP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NFYCP2 shows lower tumor expression in KIRP and KICH and higher tumor expression in COAD, LUSC and LIHC. The KIRP box plot shows higher NFYCP2 RNA expression in normal versus tumor tissue (log2 FC = −0.053, t-test p = .012).
This table shows molecular features associated with NFYCP2 in patient tissues and cancer cell lines. In patient samples, NFYCP2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
